HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cored in the act: the use of models to understand core myopathies.

Abstract
The core myopathies are a group of congenital myopathies with variable clinical expression - ranging from early-onset skeletal-muscle weakness to later-onset disease of variable severity - that are identified by characteristic 'core-like' lesions in myofibers and the presence of hypothonia and slowly or rather non-progressive muscle weakness. The genetic causes are diverse; central core disease is most often caused by mutations in ryanodine receptor 1 (RYR1), whereas multi-minicore disease is linked to pathogenic variants of several genes, including selenoprotein N (SELENON), RYR1 and titin (TTN). Understanding the mechanisms that drive core development and muscle weakness remains challenging due to the diversity of the excitation-contraction coupling (ECC) proteins involved and the differential effects of mutations across proteins. Because of this, the use of representative models expressing a mature ECC apparatus is crucial. Animal models have facilitated the identification of disease progression mechanisms for some mutations and have provided evidence to help explain genotype-phenotype correlations. However, many unanswered questions remain about the common and divergent pathological mechanisms that drive disease progression, and these mechanisms need to be understood in order to identify therapeutic targets. Several new transgenic animals have been described recently, expanding the spectrum of core myopathy models, including mice with patient-specific mutations. Furthermore, recent developments in 3D tissue engineering are expected to enable the study of core myopathy disease progression and the effects of potential therapeutic interventions in the context of human cells. In this Review, we summarize the current landscape of core myopathy models, and assess the hurdles and opportunities of future modeling strategies.
AuthorsAurora Fusto, Louise A Moyle, Penney M Gilbert, Elena Pegoraro
JournalDisease models & mechanisms (Dis Model Mech) Vol. 12 Issue 12 (12 19 2019) ISSN: 1754-8411 [Electronic] England
PMID31874912 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2019. Published by The Company of Biologists Ltd.
Chemical References
  • Alkaloids
  • Connectin
  • Muscle Proteins
  • RYR1 protein, human
  • Ryanodine Receptor Calcium Release Channel
  • SELENON protein, human
  • SEPN1 protein, mouse
  • Selenoproteins
  • TTN protein, human
  • ryanodine receptor 1, mouse
  • Ryanodine
  • cathinone
  • Protein Kinases
  • titin protein, mouse
Topics
  • Alkaloids (pharmacology)
  • Animals
  • Connectin (metabolism)
  • Disease Models, Animal
  • Disease Progression
  • Gene Expression Regulation
  • Genetic Association Studies
  • Genetic Variation
  • HEK293 Cells
  • Humans
  • Male
  • Mice
  • Mice, Transgenic
  • Muscle Proteins (metabolism)
  • Muscle Weakness
  • Muscle, Skeletal (physiopathology)
  • Myopathies, Structural, Congenital (physiopathology)
  • Myopathy, Central Core (physiopathology)
  • Ophthalmoplegia (physiopathology)
  • Protein Kinases (metabolism)
  • Ryanodine (metabolism)
  • Ryanodine Receptor Calcium Release Channel (deficiency, metabolism)
  • Selenoproteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: